Cancer specific risk in multiple sclerosis patients
dc.contributor.author | Kyritsis, A. P. | en |
dc.contributor.author | Boussios, Stergios | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Kyritsis, A. P. | en |
dc.creator | Boussios, Stergios | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:56Z | |
dc.date.available | 2018-06-22T09:53:56Z | |
dc.date.issued | 2016 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42107 | |
dc.description.abstract | Multiple sclerosis (MS) is a chronic central nervous system (CNS) autoimmune disease. Studies of cancer risk in MS patients have shown inconsistent findings. A pubmed search of the literature on cancer risk in patients with MS was conducted and found published relative studies. The majority of these studies concluded that there was overall either reduced or no increased risk of developing malignancies between patients with MS compared to the general population. However, several studies suggested that patients with MS may have reduced risk in specific cancers such as of the digestive and respiratory organs, prostate, ovary, or increased risk in breast, brain and bladder tumors. At present it is uncertain if the immunologic profile of MS patients may be related to the increased or reduced frequency of some cancers and warrants further investigation. © 2015 Elsevier Ireland Ltd. | en |
dc.language.iso | eng | en |
dc.source | Critical reviews in oncology/hematology | en |
dc.subject | Review | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Ovary cancer | en |
dc.subject | Immunosuppressive agent | en |
dc.subject | Brain tumor | en |
dc.subject | Multiple sclerosis | en |
dc.subject | Risk assessment | en |
dc.subject | Complication | en |
dc.subject | Risk | en |
dc.subject | Digestive system cancer | en |
dc.subject | Malignant neoplastic disease | en |
dc.subject | Prostate cancer | en |
dc.subject | Respiratory tract cancer | en |
dc.subject | Corticosteroid | en |
dc.subject | Bladder cancer | en |
dc.subject | Cancer risk | en |
dc.subject | Immunomodulating agent | en |
dc.subject | Immunomodulation | en |
dc.subject | Skin cancer | en |
dc.title | Cancer specific risk in multiple sclerosis patients | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.critrevonc.2015.10.002 | |
dc.description.volume | 98 | |
dc.description.startingpage | 29 | |
dc.description.endingpage | 34 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Boussios, Stergios [0000-0002-2512-6131] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2512-6131 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |